



Prof. Dr. Astrid Weyerbrock

Kontakt

Prof. Dr. Astrid Weyerbrock
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 16 72
astrid.weyerbrock@kssg.ch

Homepage

www.kssg.ch/neurochirurgie

Bereiche

Neurochirurgie

Position

Chefärztin

Funktion

Chefarzt/Chefärztin

Publikationen (61)

Ziga M, Sosnova M, Zeitzberger A, Regli L, Bozinov O, Weyerbrock A, Ratliff J, Stienen M, Maldaner N. Objective outcome measures may demonstrate continued change in functional recovery in patients with ceiling effects of subjective patient-reported outcome measures after surgery for lumbar degenerative disorders. *Spine J* 2023

Voglis S, Stienen M, Weyerbrock A, Bellut D, Regli L, Bozinov O, Sosnova M, Zeitzberger A, Ziga M, Maldaner N. Smartphone-based real-life activity data for physical performance outcome in comparison to conventional subjective and objective outcome measures after degenerative lumbar spine surgery. *Brain and Spine* 2022

Voglis S, Ziga M, Zeitzberger A, Sosnova M, Bozinov O, Regli L, Bellut D, Weyerbrock A, Stienen M, Maldaner N. Smartphone-based real-life activity data for physical performance outcome in comparison to conventional subjective and objective outcome measures after degenerative lumbar spine surgery. *Brain Spine* 2022; 2:100881.

Maldaner N, Sosnova M, Ziga M, Zeitzberger A, Bozinov O, Gautschi O, Weyerbrock A, Regli L, Stienen M. External Validation of the Minimum Clinically Important Difference in the Timed-up-and-go Test After Surgery for Lumbar Degenerative Disc Disease. *Spine (Phila Pa 1976)* 2022; 47:337-342.

Zeitzberger A, Sosnova M, Ziga M, Gautschi O, Regli L, Bozinov O, Weyerbrock A, Stienen M, Maldaner N. Distance to first symptoms measured by the 6-min walking test differentiates between treatment success and failure in patients with degenerative lumbar disorders. *Eur Spine J* 2022; 31:596-603.

Maldaner N, Sosnova M, Zeitzberger A, Ziga M, Gautschi O, Regli L, Bozinov O, Weyerbrock A, Stienen M. Responsiveness of the self-measured 6-minute walking test and the Timed Up and Go test in patients with degenerative lumbar disorders. *J Neurosurg Spine* 2021

Zeitzberger A, Sosnova M, Ziga M, Regli L, Bozinov O, Weyerbrock A, Stienen M, Maldaner N. Assessment of the Minimum Clinically Important Difference in the Smartphone-Based 6-Minute Walking Test after Surgery for Lumbar Degenerative Disc Disease. *Spine (Phila Pa 1976)* 2021

Stienen M, Maldaner N, Sosnova M, Zeitzberger A, Ziga M, Weyerbrock A, Bozinov O, Gautschi O. External Validation of the Timed Up and Go Test as Measure of Objective Functional Impairment in Patients With Lumbar Degenerative Disc Disease. *Neurosurgery* 2021; 88:E142-E149.

Maldaner N, Burkhardt J, Chiappini A, Robert T, Schatlo B, Schmid J, Maduri R, Staartjes V, Seule M, Weyerbrock A, Serra C, Stienen M, Bozinov O, Daniel R, Fandino J, Marbacher S, Zeitzberger A, Sosnova M, Goldberg J, Fung C, Bervini D, May A, Bijlenga P, Schaller K, Roethlisberger M, Rycken J, Zumofen D, D'Alonzo D, Regli L. Development of a Complication- and Treatment-Aware Prediction Model for Favorable Functional Outcome in Aneurysmal Subarachnoid Hemorrhage Based on Machine Learning. *Neurosurgery* 2021; 88:E150-E157.

Sosnova M, Zeitzberger A, Ziga M, Gautschi O, Regli L, Weyerbrock A, Bozinov O, Stienen M, Maldaner N. Patients undergoing surgery for lumbar degenerative spinal disorders favor smartphone-based objective self-assessment over paper-based patient-reported outcome measures. *Spine J* 2020

Schaller K, Finkenstädt S, Dan-Ura H, Ferrari A, Bernays R, Eisenring C, Maduri R, Mostaguir K, Kulcsar Z, Maldaner N, Woernle C, Starnoni D, Z'Graggen W, Gasche Y, Sarrafzadeh A, Jakob S, Bijlenga P, Keller E, Raabe A, Beck J, Guzman R, Mariani L, Landolt H, Hildebrandt G, Levivier M, Regli L, Baumann F, Corniola M, Gralla J, Diepers M, Nevzati E, D'Alonzo D, Reinert M, Marbacher S, Bervini D, Burkhardt J, Daniel R, Zumofen D, Smoll N, Fandino J, Fathi A, Stienen M, Fung C, Ahlborn P, Mendes Pereira V, Roethlisberger M, Goldberg J, Schöni D, Rohde V, Robert T, Sailer M, Perren F, Venier A, Woernle K, Weyerbrock A, Remonda L, Kerkeni H, Seule M, Schatlo B. Incidence and Outcome of Aneurysmal Subarachnoid Hemorrhage: The Swiss Study on Subarachnoid Hemorrhage (Swiss SOS). *Stroke* 2020; 52:344-347.

Maldaner N, Sosnova M, Zeitzberger A, Ziga M, Gautschi O, Regli L, Weyerbrock A, Stienen M, International 6WT Study Group. Evaluation of the 6-minute walking test as a smartphone app-based self-measurement of objective functional impairment in patients with lumbar degenerative disc disease. <i>J Neurosurg Spine</i> 2020;1-10.
Sosnova M, Zeitzberger A, Ziga M, Gautschi O, Weyerbrock A, Stienen M, Maldaner N. Longitudinal smartphone-based self-assessment of objective functional impairment in patients undergoing surgery for lumbar degenerative disc disease: initial experience. <i>Acta Neurochir (Wien)</i> 2020; 162:2061-2068.
Maldaner N, Tomkins-Lane C, Desai A, Zygorakis C, Weyerbrock A, Gautschi O, Stienen M. Digital transformation in spine research and outcome assessment. <i>Spine J</i> 2020; 20:310-311.
Maldaner N, Maduri R, Daniel R, Burkhardt J, Chiappini A, Robert T, Schatlo B, Seule M, Weyerbrock A, Regli L, Stienen M, Fandino J, Marbacher S, Steinsiepe V, Goldberg J, Fung C, Bervini D, May A, Bijlenga P, Schaller K, Roethlisberger M, Zumofen D, D'Alonzo D, Swiss SOS study group. Patterns of care for ruptured aneurysms of the middle cerebral artery: analysis of a Swiss national database (Swiss SOS). <i>J Neurosurg</i> 2019;1-10.
Hejrati N, Spieler D, Samuel R, Regli L, Weyerbrock A, Surbeck W. Conscious Experience and Psychological Consequences of Awake Craniotomy. <i>World Neurosurg</i> 2019
Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galdiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovan M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet</i> 2019; 393:678-688.
Guenzle J, Garrelfs N, Goeldner J, Weyerbrock A. Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro. <i>Mol Neurobiol</i> 2019
Stienen M, Schaller K, Weyerbrock A, Regli L, Prömmel P, Bellut D, Corniola M, Joswig H, Maldaner N, Gautschi O. Objective functional assessment using the "Timed Up and Go" test in patients with lumbar spinal stenosis. <i>Neurosurg Focus</i> 2019; 46:E4.
Fournier J, Weyerbrock A. Multifocal lumbar disc herniation at a single level: a potential pitfall for wrong side surgery. <i>Br J Neurosurg</i> 2018; 2018 Aug 10
Fiechter M, Weyerbrock A, Fournier J. Multifocal lumbar disc herniation at a single level: a potential pitfall for wrong side surgery. <i>Br J Neurosurg</i> 2018; 35:120-121.
Weyerbrock A. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. <i>J Cancer Res Clin Oncol</i> 2018; 2018 Aug
Stienen M, Scholtes F, Samuel R, Weil A, Weyerbrock A, Surbeck W. Different but similar: personality traits of surgeons and internists—results of a cross-sectional observational study. <i>BMJ Open</i> 2018; 8:e021310.
Weyerbrock A. Different but similar: personality traits of surgeons and internists—results of a cross-sectional observational study. <i>BMJ Open</i> 2018; 2018 Jul

Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018; 20:975-985.

Weyerbrock A. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018; 2018 Jun

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Nießen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann R, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. *J Cancer Res Clin Oncol* 2018; 144:1581-1589.

Weyerbrock A. Clinical relevance of anterior cerebral artery asymmetry in aneurysmal subarachnoid hemorrhage. *J Neurosurg* 2018; Nov;127(5)::1070--1076.

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro Oncol* 2018; 20:400-410.

Weyerbrock A. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro Oncol* 2018; 2018 Feb

Schmeiser B, Weyerbrock A, Scheiwe C, Prinz M, Steinhoff B, Wendling A, Mader I, Schulze-Bonhage A, Wagner K, Zentner J. Surgical Treatment of Mesiotemporal Lobe Epilepsy: Which Approach is Favorable?. *Neurosurgery* 2017; 81:992-1004.

Heckler M, Osterberg N, Guenzle J, Thiede-Stan N, Reichardt W, Weidensteiner C, Saavedra J, Weyerbrock A. The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation. *Tumour Biol* 2017; 39:1010428317703922.

Fedele V, Bredel M, Iavarone A, Califano A, Prinz M, Weyerbrock A, Nelander S, Kim H, Doostkam S, Platania L, Ferrarese R, Gätjens-Sanchez A, Kling E, Heiland D, Masilamani A, Dai F, Carro M. Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression. *Mol Cancer Res* 2017; 15:998-1011.

Heiland D, Weyerbrock A, Urbach H, Staszewski O, Kiselev V, Kellner E, Pfeifer D, Haaker G, Demerath T, Simon-Gabriel C, Mader I. Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. *Sci Rep* 2017; 7:43523.

Guenzle J, Wolf L, Garrelfs N, Goeldner J, Osterberg N, Schindler C, Saavedra J, Weyerbrock A. ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NFB and STAT3 inhibition in glioblastoma. *Cell Death Discov* 2017; 3:17006.

Weyerbrock A. Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. *Oncotarget* 2017; 8(7)::11083--11093.

Weyerbrock A. Whole Transcriptome Screening Reveals Myelination Deficits in Dysplastic Human Temporal Neocortex. *Cereb Cortex* 2017; Feb 1; 27(2):1558-1572.

Heiland D, Prinz M, Weyerbrock A, Carro M, Pfeifer D, Gäbelein A, Heynckes S, Masalha W, Mercas B, Delev D, Haaker G, Schnell O. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. <i>Oncotarget</i> 2017
Heiland D, Nelander S, Kling T, Weyerbrock A, Kling E, Masilamani A, Dai F, Claus R, Ferrarese R, Carro M. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. <i>Oncotarget</i> 2017; 8:6940–6954.
Jabbarli R, Reinhard M, Roelz R, Kaier K, Weyerbrock A, Taschner C, Scheiwe C, Shah M. Clinical relevance of anterior cerebral artery asymmetry in aneurysmal subarachnoid hemorrhage. <i>J Neurosurg</i> 2016;1-7.
Demerath T, Weyerbrock A, Urbach H, Egger K, Kiselev V, Mast H, Staszewski O, Reinacher P, Heiland D, Lange T, Schwarzwald R, Kellner E, Simon-Gabriel C, Mader I. Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?. <i>Neuroradiol J</i> 2016; 30:36-47.
Oehlke O, Weber W, Meyer P, Short S, Baumert B, Mader I, Weyerbrock A, Schneider-Fuchs S, Götz I, Nestle U, Schimek-Jasch T, Graf E, Mix M, Grosu A. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1). <i>BMC cancer</i> 2016; 16:769.
Kling T, Carro M, Jörnsten R, Weyerbrock A, Vasilikos I, Dai F, Heiland D, Johansson P, Ó hAilín D, Ferrarese R, Nelander S. Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma. <i>EBioMedicine</i> 2016; 12:72-85.
Günzle J, Osterberg N, Saavedra J, Weyerbrock A. Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. <i>Cell Death Dis</i> 2016; 7:e2349.
Roelz R, Strohmaier D, Jabbarli R, Kraeutle R, Egger K, Coenen V, Weyerbrock A, Reinacher P. Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma - A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy. <i>Sci Rep</i> 2016; 6:32286.
Heiland D, Weyerbrock A, Urbach H, Staszewski O, Schnell O, Pfeifer D, Kiselev V, Kellner E, Demerath T, Mader I. Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. <i>Oncotarget</i> 2016
Heiland D, Urbach H, Vasilikos I, Schwarzwald R, Lange T, Carro M, Pfeifer D, Schlosser P, Mader I, Weyerbrock A. Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme. <i>Sci Rep</i> 2016; 6:29052.
Jabbarli R, Reinhard M, Roelz R, Shah M, Niesen W, Kaier K, Taschner C, Weyerbrock A, Van Velthoven V. Intracerebral Hematoma Due to Aneurysm Rupture: Are There Risk Factors Beyond Aneurysm Location?. <i>Neurosurgery</i> 2016; 78:813–20.
Wick W, Gelfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clin Cancer Res</i> 2016; 22:4797-4806.
Strumia M, Reichardt W, Staszewski O, Heiland D, Weyerbrock A, Mader I, Bock M. Glioma vessel abnormality quantification using time-of-flight MR angiography. <i>MAGMA</i> 2016; 29:765-75.

Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciarczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. *J Clin Oncol* 2016; 34:1611–9.

Osterberg N, Plate K, Schaefer H, Doostkam S, Weyerbrock A, Niedermann G, Gaedicke S, Vacher J, Ferrara N, Machein M. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. *Neuro-oncology* 2016; 18:939–49.

Heiland D, Urbach H, Schrimpf D, Capper D, Grauvogel J, Franco P, Masalha W, Hirsch M, Staszewski O, Weyerbrock A. Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. *J Neuropathol Exp Neurol* 2016; 75:358–65.

Jabbarli R, Reinhard M, Shah M, Roelz R, Niesen W, Kaier K, Taschner C, Weyerbrock A, Van Velthoven V. Early Vasospasm after Aneurysmal Subarachnoid Hemorrhage Predicts the Occurrence and Severity of Symptomatic Vasospasm and Delayed Cerebral Ischemia. *Cerebrovasc Dis* 2016; 41:265–72.

Donkels C, Zentner J, Weyerbrock A, Schulze-Bonhage A, Prinz M, Nakagawa J, Huber S, Janz P, Pfeifer D, Haas C. Whole Transcriptome Screening Reveals Myelination Deficits in Dysplastic Human Temporal Neocortex. *Cereb Cortex* 2016

Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M, Weyerbrock A, Nieder C, Grosu A. Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. *Clin Neurol Neurosurg* 2016; 142:81–6.

Jabbarli R, Reinhard M, Roelz R, Shah M, Niesen W, Kaier K, Taschner C, Weyerbrock A, Velthoven V. The predictors and clinical impact of intraventricular hemorrhage in patients with aneurysmal subarachnoid hemorrhage. *Int J Stroke* 2016; 11:68–76.

Scholz A, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh J, Ullrich E, Mittelbronn M, Plate K, Krex D, Herrlinger U, Glas M, Harter P, Cremer S, Yalcin B, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach J, Trojan J, Reiss Y. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naïve and bevacizumab-resistant glioblastoma. *EMBO Mol Med* 2015; 8:39–57.

Ringel F, Simon M, Meyer B, Schucht P, Senft C, Westermaier T, Weyerbrock A, Misch M, Bock H, Krex D, Sabel M, Pape H. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. *Neuro-oncology* 2015; 18:96–104.

Weyerbrock A, Keefer L, Saavedra J, Bette S, Werres A, Kogias E, Baumer B, Psarras N, Osterberg N, Papazoglou A. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas. *Neurosurgery* 2012; 70:497–510; discussion 510.

Kogias E, Osterberg N, Baumer B, Psarras N, Koentges C, Papazoglou A, Saavedra J, Keefer L, Weyerbrock A. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase- π -activated nitric oxide donor PABA/NO in malignant gliomas. *Int J Cancer* 2011; 130:1184–94.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch